A new joint project will develop precision medicines for blood cancers and solid tumors by utilizing immunotherapies targeting natural killer (NK) cells.
In collaboration between Yissum, the technology-transfer company of the Hebrew University of Jerusalem, biopharmaceutical company Cytovia Therapeutics will sponsor a research program to develop multi-specific antibodies targeting both NK cells and the tumor antigen.
